| anastrozole |
II-6002/13,10,2009 |
ARMOTRAZ, Film coated tablet, 1, mg, Pack: 10 |
МС Фарма АД, България |
МС Фарма АД, България |
51.69 |
10.34 |
62.03 |
4% |
2.07 |
53.76 |
10.75 |
64.51 |
16% |
8.27 |
62.03 |
12.41 |
74.44 |
промяна на обстоятелствата КЦ-1764/10.09.2010 ; HCP-365/03.07.2013 |
КЦ-1267/29.12.2009 |
06.01.2010 |
06.01.2010 |
Неактивен |
859 |
| Acarbose |
20150219 |
Aroba, Tablet, 100, mg, Pack: 30 |
Чайкафарма Висококачествените лекарства АД, България |
Чайкафарма Висококачествените лекарства АД, София, България |
5.75 |
1.15 |
6.9 |
7% |
0.4 |
6.15 |
1.23 |
7.38 |
20% |
1.15 |
7.3 |
1.46 |
8.76 |
|
НСР-7522/19.11.2015.; НСР-18364/05.04.2019 |
20.04.2019 |
02.05.2019 |
Активен |
4125 |
| Acarbose |
20150219 |
Aroba, Tablet, 100, mg, Pack: 30 |
Чайкафарма Висококачествените лекарства АД, България |
Чайкафарма Висококачествените лекарства АД, София, България |
5.45 |
1.09 |
6.54 |
7% |
0.38 |
5.83 |
1.17 |
7 |
20% |
1.09 |
6.92 |
1.38 |
8.3 |
|
НСР-7522/19.11.2015. |
05.12.2015 |
05.12.2015 |
Неактивен |
4125 |
| Exemestane |
20000458 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Europe MA EEIG, Белгия |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
49.66 |
9.93 |
59.59 |
4% |
1.99 |
51.65 |
10.33 |
61.98 |
16% |
7.95 |
59.6 |
11.92 |
71.52 |
промяна обстоятелства НСР-9875/21.07.2016; НСР-17316/22.11.2018 |
НСР-5943/01.04.2015.; НСР 9551/17.06.2016; НСР-14310/26.10.2017 |
10.11.2017 |
02.01.2019 |
Активен |
3734 |
| Exemestane |
20000458 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Europe MA EEIG, Белгия |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
49.66 |
9.93 |
59.59 |
4% |
1.99 |
51.65 |
10.33 |
61.98 |
16% |
7.95 |
59.6 |
11.92 |
71.52 |
промяна обстоятелства НСР-9875/21.07.2016; НСР-17316/22.11.2018 |
НСР-5943/01.04.2015.; НСР 9551/17.06.2016; НСР-14310/26.10.2017 |
10.11.2017 |
02.01.2019 |
Неактивен |
3734 |
| Exemestane |
20000458 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
49.66 |
9.93 |
59.59 |
4% |
1.99 |
51.65 |
10.33 |
61.98 |
16% |
7.95 |
59.6 |
11.92 |
71.52 |
промяна обстоятелства НСР-9875/21.07.2016 |
НСР-5943/01.04.2015.; НСР 9551/17.06.2016; НСР-14310/26.10.2017 |
10.11.2017 |
02.12.2017 |
Неактивен |
3734 |
| Exemestane |
20000458 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
72.23 |
14.45 |
86.68 |
4% |
2.89 |
75.12 |
15.02 |
90.14 |
16% |
11.56 |
86.68 |
17.34 |
104.02 |
промяна обстоятелства НСР-9875/21.07.2016 |
НСР 9551/17.06.2016 |
02.08.2016 |
02.09.2016 |
Неактивен |
3734 |
| Exemestane |
II-11850/14.11.2005 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
72.23 |
14.45 |
86.68 |
4% |
2.89 |
75.12 |
15.02 |
90.14 |
16% |
11.56 |
86.68 |
17.34 |
104.02 |
|
НСР-5943/01.04.2015.; НСР 9551/17.06.2016 |
02.08.2016 |
02.08.2016 |
Неактивен |
3734 |
| Exemestane |
II-11850/14.11.2005 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
82.22 |
16.44 |
98.66 |
4% |
3.29 |
85.51 |
17.1 |
102.61 |
16% |
13.16 |
98.67 |
19.73 |
118.4 |
|
НСР-5943/01.04.2015. |
16.04.2015 |
16.04.2015 |
Неактивен |
3734 |
| Exemestane |
II-11850/14.11.2005 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Europe MA EEIG, Обединено Кралство |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
99.49 |
19.9 |
119.39 |
4% |
3.98 |
103.47 |
20.69 |
124.16 |
16% |
15.92 |
119.39 |
23.88 |
143.27 |
|
НСР-2216/20.12.2013 |
04.01.2014 |
04.01.2014 |
Неактивен |
3734 |
| Exemestane |
II-11850/14.11.2005 |
Aromasin, Film coated tablet, 25, mg, Pack: 30 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Italia S.r.l., Via del Commercio, Marino del Tronto, Ascoli Piceno, Italy |
129.16 |
25.83 |
154.99 |
4% |
5.17 |
134.33 |
26.87 |
161.2 |
16% |
20.67 |
155 |
31 |
186 |
|
КЦ-672/06.03.2009 |
23.03.2009 |
23.03.2009 |
Неактивен |
3734 |
| Fluticasone |
20150322 |
Arquist, Pressurised inhalation, suspension, 250 mcg/dose - 120 doses, mcg, Pack: 1 |
Cipla Europe NV, Белгия |
S & D Pharma CZ, spol.s.r.o., Чешка Република; Cipla(EU) Limited, Обединено Кралство; Cipla Europe NV, Белгия |
23.49 |
4.7 |
28.19 |
6% |
1.41 |
24.9 |
4.98 |
29.88 |
18% |
4.23 |
29.13 |
5.83 |
34.96 |
Промяна на обстоятелства НСР-19755/04.09.2019 |
НСР-14170/13.10.2017; НСР-17524/13.12.2018 |
28.12.2018 |
02.10.2019 |
Активен |
15903 |
| Fluticasone |
20150322 |
Arquist, Pressurised inhalation, suspension, 250 mcg/dose - 120 doses, mcg, Pack: 1 |
S&D Pharma CZ spoI. s.r.o., Чешка република |
S & D Pharma CZ, spol.s.r.o., Чешка Република; Cipla(EU) Limited, Обединено Кралство; Cipla Europe NV, Белгия |
23.49 |
4.7 |
28.19 |
6% |
1.41 |
24.9 |
4.98 |
29.88 |
18% |
4.23 |
29.13 |
5.83 |
34.96 |
|
НСР-14170/13.10.2017; НСР-17524/13.12.2018 |
28.12.2018 |
02.01.2019 |
Неактивен |
15903 |
| Fluticasone |
20150322 |
Arquist, Pressurised inhalation, suspension, 250 mcg/dose - 120 doses, mcg, Pack: 1 |
S&D Pharma CZ spoI. s.r.o., Чешка република |
S & D Pharma CZ, spol.s.r.o., Чешка Република; Cipla(EU) Limited, Обединено Кралство; Cipla Europe NV, Белгия |
23.72 |
4.74 |
28.46 |
6% |
1.42 |
25.14 |
5.03 |
30.17 |
18% |
4.27 |
29.41 |
5.88 |
35.29 |
|
НСР-14170/13.10.2017 |
28.10.2017 |
02.11.2017 |
Неактивен |
15903 |
| Ofatumumab |
EU/1/10/625/001 |
Arzerra, Concentrate for solution for infusion, 100 mg (20 mg/ml), 5 ml, mg, Pack: 3 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
1193.8 |
238.76 |
1432.56 |
4% |
10 |
1203.8 |
240.76 |
1444.56 |
16% |
25 |
1228.8 |
245.76 |
1474.56 |
промяна в обстоятелствата НСР-6998/24.08.2015 |
НСР-4324/05.08.2014; НСР-9196/05.05.2016; НСР-19047/27.06.2019 |
20.05.2016 |
02.08.2019 |
Заличен |
3106 |
| Ofatumumab |
EU/1/10/625/001 |
Arzerra, Concentrate for solution for infusion, 100 mg (20 mg/ml), 5 ml, mg, Pack: 3 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
1193.8 |
238.76 |
1432.56 |
4% |
10 |
1203.8 |
240.76 |
1444.56 |
16% |
25 |
1228.8 |
245.76 |
1474.56 |
промяна в обстоятелствата НСР-6998/24.08.2015 |
НСР-4324/05.08.2014; НСР-9196/05.05.2016 |
20.05.2016 |
02.06.2016 |
Неактивен |
3106 |
| Ofatumumab |
EU/1/10/625/001 |
Arzerra, Concentrate for solution for infusion, 100 mg (20 mg/ml), 5 ml, mg, Pack: 3 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
1196.34 |
239.27 |
1435.61 |
4% |
10 |
1206.34 |
241.27 |
1447.61 |
16% |
25 |
1231.34 |
246.27 |
1477.61 |
промяна в обстоятелствата НСР-6998/24.08.2015 |
НСР-4324/05.08.2014 |
20.08.2014 |
20.08.2014 |
Неактивен |
3106 |
| Ofatumumab |
EU/1/10/625/001 |
Arzerra, Concentrate for solution for infusion, 100 mg (20 mg/ml), 5 ml, mg, Pack: 3 vials with 2 extension sets |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
1208.7 |
241.74 |
1450.44 |
4% |
10 |
1218.7 |
243.74 |
1462.44 |
16% |
25 |
1243.7 |
248.74 |
1492.44 |
|
НСР-2265/27.12.2013 |
30.12.2013 |
30.12.2013 |
Неактивен |
3106 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3806.67 |
761.33 |
4568 |
4% |
10 |
3816.67 |
763.33 |
4580 |
16% |
25 |
3841.67 |
768.33 |
4610 |
|
НСР-8220/22.02.2016; НСР-10753/27.10.2016; НСР-14823/18.01.2018; НСР-16931/04.10.2018; НСР-19047/27.06.2019 |
19.10.2018 |
02.08.2019 |
Заличен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3806.67 |
761.33 |
4568 |
4% |
10 |
3816.67 |
763.33 |
4580 |
16% |
25 |
3841.67 |
768.33 |
4610 |
|
НСР-8220/22.02.2016; НСР-10753/27.10.2016; НСР-14823/18.01.2018; НСР-16931/04.10.2018 |
19.10.2018 |
02.11.2018 |
Неактивен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3867.32 |
773.46 |
4640.78 |
4% |
10 |
3877.32 |
775.46 |
4652.78 |
16% |
25 |
3902.32 |
780.46 |
4682.78 |
|
НСР-8220/22.02.2016; НСР-10753/27.10.2016; НСР-14823/18.01.2018 |
02.02.2018 |
02.03.2018 |
Неактивен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3883.16 |
776.63 |
4659.79 |
4% |
10 |
3893.16 |
778.63 |
4671.79 |
16% |
25 |
3918.16 |
783.63 |
4701.79 |
|
НСР-8220/22.02.2016; НСР-10753/27.10.2016 |
11.11.2016 |
02.12.2016 |
Неактивен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3936.4 |
787.28 |
4723.68 |
4% |
10 |
3946.4 |
789.28 |
4735.68 |
16% |
25 |
3971.4 |
794.28 |
4765.68 |
|
НСР-8220/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3972.04 |
794.41 |
4766.45 |
4% |
10 |
3982.04 |
796.41 |
4778.45 |
16% |
25 |
4007.04 |
801.41 |
4808.45 |
промяна в обстоятелствата НСР-6997/24.08.2015 |
НСР-6548/24.06.2015 |
10.07.2015 |
10.07.2015 |
Неактивен |
3107 |
| Ofatumumab |
EU/1/10/625/003 |
Arzerra, Concentrate for solution for infusion, 1000 mg (20 mg/ml), 50 ml, mg, Pack: 1 vials with 2 extension sets |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Operations UK Ltd.,Harmire Road, Barnard Castle Durham, DL12 8DT, United Kingdom |
3979.02 |
795.8 |
4774.82 |
4% |
10 |
3989.02 |
797.8 |
4786.82 |
16% |
25 |
4014.02 |
802.8 |
4816.82 |
|
НСР-4323/05.08.2014 |
20.08.2014 |
20.08.2014 |
Неактивен |
3107 |